N/A
Completed N=4,467
EZETROL® Re-examination Study (MK0653-175)(COMPLETED)
Source: ClinicalTrials.gov NCT01070953 ↗Enrolled (actual)
4,467
Serious AEs
1.0%
Results posted
Nov 2011
Primary outcomePrimary: Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation — 257 participants
Summary
This survey is conducted for preparing application materials for re-examination under the Pharmaceutical Affairs Laws and its Enforcement Regulation, its aim is to reconfirm the clinical usefulness of EZETROL® through collecting the safety information according to the Re-examination Regulation for New Drugs.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Participants With Any Clinical and/or Laboratory Adverse Experience While Being Treated With EZETROL® Within 14 Days After Treatment Discontinuation |
257 | — |
| PRIMARY Mean Percent Change From Baseline to Treatment in Lipid Parameters |
-21.23; 3.47; -24.06; -10.37 | — |
| PRIMARY Overall Efficacy Evaluation of EZETROL® |
3029; 241; 39; 3309 | — |
Eligibility Criteria
Inclusion Criteria
- Participants Who Receives EZETROL® In Usual Medical Practice
Data sourced from ClinicalTrials.gov (NCT01070953). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.